pDONR223-BCKDK Citations (2)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-BCKDK

Articles
BCKDK of BCAA Catabolism Cross-talking With the MAPK Pathway Promotes Tumorigenesis of Colorectal Cancer. Xue P, Zeng F, Duan Q, Xiao J, Liu L, Yuan P, Fan L, Sun H, Malyarenko OS, Lu H, Xiu R, Liu S, Shao C, Zhang J, Yan W, Wang Z, Zheng J, Zhu F. EBioMedicine. 2017 Jun;20:50-60. doi: 10.1016/j.ebiom.2017.05.001. Epub 2017 May 4. PubMed
BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway. Li H, Yu D, Li L, Xiao J, Zhu Y, Liu Y, Mou L, Tian Y, Chen L, Zhu F, Duan Q, Xue P. J Oncol. 2022 Apr 22;2022:3691635. doi: 10.1155/2022/3691635. eCollection 2022. PubMed

If you have published an article using this material, please email us at to have your article added to this page.